Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 2: GI, lower digestive

315O - Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Date

12 Sep 2022

Session

Proffered Paper session 2: GI, lower digestive

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Yasutoshi Kuboki

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

Y. Kuboki1, R. Yaeger2, M.G. Fakih3, J.H. Strickler4, T. Masuishi5, E.J. Kim6, C.M. Bestvina7, C.J. Langer8, J.C. Krauss9, S. Puri10, P. Cardona11, E. Chan12, Q. Tran12, D.S. Hong13

Author affiliations

  • 1 Experimental Therapeutics And Gi Oncology Department, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Department Of Medicine, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 3 Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
  • 4 Department Of Medicine, Duke University Medical Center, 27710 - Durham/US
  • 5 Clinical Oncology Dept., Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 6 Hematology/oncology Internal Medicine, UC Davis Comprehensive Cancer Center, 95817 - Sacramento/US
  • 7 Department Of Medicine - Section Of Hematology/oncology, University of Chicago, 60637-1470 - Chicago/US
  • 8 Hematology/oncology, University of Pennsylvania, 19104 - Philadelphia/US
  • 9 Hematology/oncology Internal Medicine, University of Michigan, 48109 - Ann Arbor/US
  • 10 Medicine/ Hematology And Oncology, Huntsman Cancer Institute, 84132 - Salt Lake City/US
  • 11 Clinical Pharmacology, Modeling And Simulation, Amgen Inc., 91320 - Thousand Oaks/US
  • 12 Research And Development, Amgen Inc., 91320 - Thousand Oaks/US
  • 13 Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 77035 - Houston/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 315O

Background

Sotorasib (Soto), a KRASG12C inhibitor, showed modest clinical activity as monotherapy in heavily pretreated patients (pts) with KRAS G12C-mutated colorectal cancer (CRC) in the CodeBreaK 100 phase II study, with a 9.7% objective response rate (ORR). Early data from the CodeBreaK 101 phase Ib dose exploration (n=8) and expansion (n=18) cohorts showed promising antitumor activity for the combination of Soto and panitumumab (Pmab), an EGFR antibody, in chemorefractory KRAS G12C-mutated metastatic CRC (mCRC). Here, we report results from the fully enrolled dose expansion cohort of 40 pts with refractory mCRC.

Methods

CodeBreaK 101 (NCT04185883) subprotocol H includes dose exploration and expansion in multiple cohorts. Key eligibility criteria for the refractory mCRC cohort included progression on or after prior fluoropyrimidine, oxaliplatin, irinotecan and an anti-angiogenic agent. Primary endpoint is safety. Secondary endpoints include antitumor activity, progression-free survival (PFS), overall survival (OS), and pharmacokinetics (PK).

Results

As of March 25, 2022, 40 pts (75% female, median age 57.5 years) were enrolled and received oral Soto 960 mg daily and Pmab 6 mg/kg IV every 2 weeks. Median prior lines of therapy was 2. Treatment-related adverse events (TRAEs) of any grade occurred in 37 (92.5%) pts. Grade 3 TRAEs occurred in 9 (22.5%) pts; related to Soto and Pmab in 6 (15%) and 8 (20%) pts, respectively. No TRAEs were Grade >3 or resulted in treatment discontinuation. Safety findings were consistent with known profiles of Soto and Pmab. Confirmed ORR was 30% (95% CI: 16.6, 46.5). Disease control rate was 90% (95% CI: 76.3, 97.2). Tumor shrinkage of any magnitude was observed in 35 (87.5%) pts. Soto PK exposures were consistent to those observed in monotherapy studies.

Conclusions

This dataset provides further evidence of safety and tolerability for the combination of Soto and Pmab in heavily pretreated pts with KRAS G12C-mutated mCRC, with 3-fold higher response than previously observed with Soto monotherapy, supporting further development of this combination. Longer follow up data with duration of response, PFS, and OS will be presented.

Clinical trial identification

NCT04185883.

Editorial acknowledgement

Medical writing support was provided by Tim Harrison, PharmD (Amgen Inc.).

Legal entity responsible for the study

Amgen Inc.

Funding

Amgen Inc.

Disclosure

Y. Kuboki: Financial Interests, Institutional, Writing Engagements: Amgen; Financial Interests, Institutional, Research Grant: Taiho, Astellas, Lilly, Takeda, Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim, Chugai, Genmab, GlaxoSmithKline, Incyte, AbbVie; Financial Interests, Personal, Other, Consulting fees: Taiho, Takeda, Boehringer Ingelheim, Amgen; Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Taiho, Ono, Lilly, Bristol-Myers Squibb. R. Yaeger: Financial Interests, Personal, Advisory Role: Natera, Array BioPharma/Pfizer, Mirati Therapeutics; Financial Interests, Institutional, Research Grant: Array BioPharma/Pfizer, Boehringer Ingelheim, Mirati Therapeutics. M.G. Fakih: Financial Interests, Institutional, Research Grant: Genentech, Verastem; Financial Interests, Personal, Other, Consulting fees: AstraZeneca, Bayer Corporation, HalioDX, Incyte Corporation, Mirati, Pfizer, Inc., PsiOxus, Taiho Oncology, Zhuhai Yufan Biotech; Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Amgen, Inc., Guardant360; Financial Interests, Personal, Other, Participation on a Data Safety Monitoring Board or Advisory Board: Amgen, Inc., Bayer Corporation, GlaxoSmithKline, Nouscom, Roche/Genentech, Seattle Genetics; Financial Interests, Institutional, Other, Study-related drugs supplied to my institution: Bristol Myers Squibb. J.H. Strickler: Financial Interests, Personal, Advisory Board: SeaGen, AstraZenca, Amgen, Pfizer, Bayer, AbbVie, Natera, Viatris, Inivata, Silverback Therapeutics; Financial Interests, Personal, Other, Consulting: Mereo, GSK, Pionyr Immunotherapeutics; Financial Interests, Institutional, Invited Speaker: SeaGen, Roche Genentech, AbbVie, AstraZeneca, Amgen, AStar D3, Sanofi, Curegenix, Nektar, Leap Therapeutics, Daiichi Sankyo, Erasca, Gossamer Bio, Silverback Therapeutics. T. Masuishi: Financial Interests, Institutional, Research Grant: MSD, Daiichi Sankyo, Ono, Novartis, Amgen, Syneos Health Clinical, Boehringer Ingelheim, Pfizer, Cimic Shift Zero, Eli Lilly; Financial Interests, Personal, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Takeda, Chugai, Merck BioPharma, Taiho, Bayer, Lilly Japan, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono, Bristol-Myers Squibb. E.J. Kim: Financial Interests, Institutional, Research Grant: NGM, Erytech, Fibrogen, Eureka, Merck, BMS, Astellas, Boston Biomedical, AZ, Celgene, Halozyme, Samumed, Epicentrx; Financial Interests, Personal, Other, Consulting fees: Eisai, Taiho, Celgene, Lilly; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Other, Participation on a Data Safety Monitoring Board or Advisory Board: Lilly. C.M. Bestvina: Financial Interests, Institutional, Research Grant: AstraZeneca, BMS; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, CVS, Genentech, Jazz, JNJ, Novartis, Pfizer, Regeneron/Sanofi, Seattle Genetics, Takeda; Financial Interests, Personal, Other, Speakers Fee: Merck; Financial Interests, Personal, Other, Support for attending meetings and/or travel: EMD Serono. C.J. Langer: Financial Interests, Personal, Advisory Role: Abbott Biotherapeutics, ARIAD, AstraZeneca, Bayer/Onyx, Bristol-Myers Squibb, Cancer Support Community, Celgene, Clarient, Clovis Oncology, Genentech/Roche, Gilead Sciences, Lilly/ImClone, Merck, Novocure, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Advantagene, ARIAD, Celgene, Clovis Oncology, Genentech/Roche, GlaxoSmithKline, Inovio Pharmaceuticals, Lilly, Merck, Stem CentRx, Trizell; Other: Amgen, Lilly, Peregrine Pharmaceuticals, Synta; Financial Interests, Personal, Other, Honoraria: AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Lilly/ImClone, Merck, Takeda Science Foundation. J.C. Krauss: Financial Interests, Institutional, Invited Speaker, Site PI for clinical trial: Sumitomo Dainippon Pharma Oncology, Inc., Novartis Pharmaceuticals Corporation, Amgen, Inc., Merck Sharp & Dohme Res. Labs TO Nsabp Foundation; Financial Interests, Institutional, Invited Speaker, Site PI for clinical Trial: Hutchison Medipharma Limited TO Syneos Health, LLC, Ignyta, Inc. TO Quintiles, Inc; Financial Interests, Institutional, Invited Speaker, Site PI for Clinical Trial: Isofol Medical AB; Financial Interests, Institutional, Invited Speaker, Site PI for a clinical trial: AbbVie, Inc., Bristol-Myers Squibb, MedImmune, Pfizer, Daiichi Sankyo Company, Ltd TO Syneos Health, LLC. S. Puri: Financial Interests, Personal, Other, Consulting fees: AstraZeneca, G1 Therapeutics. P. Cardona: Financial Interests, Personal, Stocks/Shares: Amgen; Financial Interests, Personal, Full or part-time Employment: Amgen. E. Chan: Financial Interests, Personal, Stocks/Shares: Amgen; Financial Interests, Personal, Full or part-time Employment: Amgen. Q. Tran: Financial Interests, Personal, Stocks/Shares: Amgen; Financial Interests, Personal, Full or part-time Employment: Amgen. D.S. Hong: Financial Interests, Personal, Other, Consultancy role: Amgen; Financial Interests, Institutional, Research Grant: Amgen, AbbVie, Adaptimmune, Adlai-Nortye, AstraZeneca, Bayer, Daiichi Sankyo, Deciphera, Eisai, Endeavor, Erasca, F. Hoffmann-La Roche, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, TCR2, Teckro, Turning Point Therapeutics, VM Oncology, Bristol-Myers Squibb; Financial Interests, Personal, Other, Consulting: Adaptimmune, Alpha Insights, Acuta, Alkermes, Aumbiosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, COR2ed, COG, Cowen, Ecor1, Gennao Bio, Genentech, Gilead, GLG, Group H, Guidepoint, HCW Precision, Immunogen, Infinity, Janssen, Liberium, MedaCorp, Medscape, Numab, Oncologia Brasil, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, RAIN, Seattle Genetics, ST Cube, Takeda, Tavistock, Trieza Therapeutics, Turning Point, WebMD, YingLing Pharma, Ziopharm; Financial Interests, Personal, Other, Support for attending meetings and/or travel: Bayer, Genmab, AACR, ASCO, SITC, Telperian; Financial Interests, Personal, Advisory Role: Molecular Match; Financial Interests, Personal, Other, Founder Advisor: OncoResponse, Telperian.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.